Although the development of anti-VEGF medications gave people with AMD fresh hope, the necessity of long-term therapy and the frequency of injections place a considerable financial and logistical burden on both individuals and the healthcare system [15]. This evidence concerns the gene VEGFA and age-related macular degeneration.